Hence, we are convinced that the use of the Bi-FAP/HER2-IL conveys properties which can be combined for image-guided delivery of drugs to tumor and tumor microenvironment cells and also to manage resistance of drugs that exert their effects within the nuclei of tumor cells but are limited by restricted nuclear access. This evidence concerns the gene FAP and neoplasm.